Tuesday, October 4, 2022 Daily Archives

Japan doles out $1.5bn to strengthen vaccine manufacturing

by

CDMO AGC Bio is among the 17 companies selected by Japan’s Ministry of Economy, Trade, and Industry (METI) to support pandemic-ready vaccine manufacturing. As part of Japan’s fiscal 2021 budget, the ‘Biopharmaceutical Manufacturing Base Development Project for Strengthening Vaccine Production System’ invited applications from academia and industry to help secure bioproduction for future pandemics. The aim is to develop a Japan-based production network – from formulation, to fill-finish – with dual-use equipment that manufactures biopharmaceuticals that meet corporate needs during…

October 4, 2022

Supply chain weight grows as CGTs reach ‘critical inflection point’

by

Cell and gene therapy developers should start planning manufacturing and supply chains at least three years ahead of commercial launch, according to new analysis. The research – by consulting group McKinsey – said the cell and gene therapy sector is at a “critical inflection point” with regards to bringing products to market and sought to identify steps likely to increase the chance of a successful launch. And the key finding is that products for which the supply chains are planned…

October 4, 2022

Thermo Fisher launches Dynabeads tech to support mRNA production

by

Thermo Fisher Scientific has introduced a customized Dynabeads solutions, which it says supports synthesis and purification of mRNA for manufacturing and vaccine development. According to the firm, the Dynabeads Streptavidin for in vitro transcription and Dynabeads for carboxylic acid for RNA purification solutions can support messenger RNA (mRNA) synthesis and purification for vaccine development and production. Furthermore, Thermo Fisher says that when combined with its TheraPure portfolio of enzymes and nucleotides, it provides a simplified workflow that allows mRNA firms…

October 4, 2022

Testing times: WuXi ATU investments ready to support CGT cascade

by

WuXi Advanced Therapies has highlighted its expanded cell and gene therapy testing capabilities in preparation for as many as 200 products reaching the market in the next seven years. “Just 18 months ago there was a little over 1,100 compounds in development. Now there are over 2,000,” Michael Stump, executive director of Testing Operations at WuXi Advanced Therapies said at Biotech Week Boston. “Even a 5-10% success rate, we’re looking at 200 modalities coming into the market in the next…

October 4, 2022